Compare VNCE & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNCE | XBIT |
|---|---|---|
| Founded | 2002 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.0M | 69.8M |
| IPO Year | 2013 | 2015 |
| Metric | VNCE | XBIT |
|---|---|---|
| Price | $6.12 | $2.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $5.17 | N/A |
| AVG Volume (30 Days) | ★ 125.7K | 40.7K |
| Earning Date | 04-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.45 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $300,007,000.00 | N/A |
| Revenue This Year | $5.86 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.23 | N/A |
| 52 Week Low | $1.28 | $2.09 |
| 52 Week High | $8.20 | $3.61 |
| Indicator | VNCE | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 47.68 | 42.92 |
| Support Level | $6.04 | $2.27 |
| Resistance Level | $6.89 | $2.42 |
| Average True Range (ATR) | 0.44 | 0.05 |
| MACD | -0.12 | 0.00 |
| Stochastic Oscillator | 36.51 | 47.06 |
Vince Holding Corp is a fashion brand that is engaged in wholesale and retail delivery of luxury essentials like women's and men's apparel, women's and men's footwear, and handbags. Its offers women's collections of luxurious cashmere sweaters and silk blouses, leather and suede leggings and jackets, dresses, denim, pants, tanks and t-shirts, and a growing assortment of outerwear. It focuses on developing an elevated collection of Vince apparel and accessories to serve the luxurious need of the customer. The company manages its business in three segments namely Vince Wholesale and Vince Direct-to-consumer. It operates its e-commerce business through its website. Maximum of its revenue generated from Vince Wholesale segment.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.